BackgroundCheck.run
Search For

Sandeep Dutta, 5686 Via Mirabella, Newbury Park, CA 91320

Known as:
Sanjoy Dutta Sandeep Duta
Related to:
Saptarshi Dutta 24 Sanjoy Dutta 59 Namrata Dutta 47 Soumya Dutta 52 Bhakti Dutta 83

Sandeep Dutta Phones & Addresses

86 Via Mirabella, Newbury Park, CA 91320   

Thousand Oaks, CA   

Lincolnshire, IL   

7303 Clem Dr, Gurnee, IL 60031    847-8558062   

Buffalo, NY   

Newark, DE   

Waukegan, IL   

Nutley, NJ   

Lane, IL   

Bloomfield, NJ   

Get Report
Control this profile

Mentions for Sandeep Dutta

Sandeep Dutta resumes & CV records

Resumes

Sandeep Dutta Photo 25

Partner At Mckinsey & Company

Position:
Partner at McKinsey & Company
Location:
United States
Industry:
Computer Software
Work:
McKinsey & Company
Partner
Education:
Massachusetts Institute of Technology 2001 - 2003
Sandeep Dutta Photo 26

Adjunct Associate Professor, Pharmaceutical Sciences And Experimental Therapeutics,College Of Pharmacy

Location:
86 Via Mirabella, Newbury Park, CA 91320
Industry:
Pharmaceuticals
Work:
University of Iowa
Adjunct Associate Professor, Pharmaceutical Sciences and Experimental Therapeutics,College of Pharmacy Amgen Oct 2016 - Dec 11, 2016
Executive Director, Translational Medicine, and Global Head, Clinical Pharmacology and Modeling and Simulation Abbvie Apr 2012 - Nov 2015
Senior Director and Senior Research Fellow, Clinical Pkpd and Pharmacogenetics and Genomics and Bioinformatics Abbvie Jan 2011 - Apr 2012
Senior Director and Research Fellow, Clinical Pk and Pd and Pharmacogenetics and Bioinformatics Abbott Apr 1, 2007 - Jan 1, 2011
Director and Research Fellow, Neuroscience, Pain and Hepatitis-C Clinical Pkpd Abbott Aug 1, 2004 - Apr 1, 2007
Associate Director and Associate Research Fellow, Neuroscience and Pain Clinical Pkpd Abbott Oct 2003 - Aug 2004
Section Manager and Associate Research Fellow, Neuroscience and Pain Clinical Pkpd
Education:
University at Buffalo 1992 - 1997
Doctorates, Doctor of Philosophy Jadavpur University 1988 - 1992
Bachelors, Bachelor of Pharmacy, Pharmacy Calcutta University, Kolkata 1987 - 1988
Saint James High School, Calcutta/Kolkata 1985 - 1987
Julien Day School, Calcutta/Kolkata 1983 - 1985
Skills:
Drug Development, Clinical Development, Pharmaceutical Industry, Clinical Trials, Clinical Pharmacology, Clinical Research, Neuroscience, Pharmacokinetics, Pharmacology, Biotechnology, Pharmacometrics, R&D, Fda, Protocol, Regulatory Submissions, Ind
Languages:
English
Sandeep Dutta Photo 27

Online Marketing Manager

Work:

Online Marketing Manager
Sandeep Dutta Photo 28

Sandeep Dutta

Publications & IP owners

Us Patents

Controlled Release Formulation Of Divalproex Sodium

US Patent:
6511678, Jan 28, 2003
Filed:
Dec 22, 2000
Appl. No.:
09/748567
Inventors:
Yihong Qiu - Gumee IL
J. Daniel Bollinger - Libertyville IL
Sandeep Dutta - Waukegan IL
Howard S. Cheskin - Glencoe IL
Kevin R. Engh - Kenosha WI
Richard P. Poska - Mundelein IL
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 900
US Classification:
424464, 442465, 442489, 442499, 442468, 442470
Abstract:
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

Controlled Release Formulation Of Divalproex Sodium

US Patent:
6528090, Mar 4, 2003
Filed:
Dec 22, 2000
Appl. No.:
09/748566
Inventors:
Yihong Qiu - Gumee IL
J. Daniel Bollinger - Libertyville IL
Howard S. Cheskin - Glencoe IL
Sandeep Dutta - Waukegan IL
Kevin R. Engh - Kenosha WI
Richard P. Poska - Mundelein IL
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 900
US Classification:
424464, 424465, 424489, 424499, 424468, 424470
Abstract:
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

Controlled Release Formulation Of Divalproex Sodium

US Patent:
6713086, Mar 30, 2004
Filed:
Aug 8, 2002
Appl. No.:
10/215142
Inventors:
Yihong Qiu - Gumee IL
J. Daniel Bollinger - Libertyville IL
Howard S. Cheskin - Glencoe IL
Sandeep Dutta - Waukegan IL
Kevin R. Engh - Kenosha IL
Richard P. Poska - Mundelein IL
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 900
US Classification:
424464, 424465, 424468, 424470, 424489, 424499
Abstract:
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

Controlled Release Formulation Of Divalproex Sodium

US Patent:
6720004, Apr 13, 2004
Filed:
Aug 8, 2002
Appl. No.:
10/215141
Inventors:
Yihong Qiu - Gumee IL
J. Daniel Bollinger - Libertyville IL
Sandeep Dutta - Waukegan IL
Howard S. Cheskin - Glencoe IL
Kevin R. Engh - Kenosha WI
Richard P. Poska - Mundelein IL
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 900
US Classification:
424464, 424465, 424468, 424470, 424489, 424499
Abstract:
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

Treatment Of Attention-Deficit/Hyperactivity Disorder

US Patent:
8222278, Jul 17, 2012
Filed:
May 29, 2009
Appl. No.:
12/475440
Inventors:
Earle E. Bain - Libertyville IL, US
Walid M. Abi-Saab - Dornach, CH
Sandeep Dutta - Gurnee IL, US
Tushar S. Garimella - Skokie IL, US
Walid M. Awni - Libertyville IL, US
Mario D. Saltarelli - Lake Bluff IL, US
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 31/44
US Classification:
514338
Abstract:
3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3. 2. 0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder.

Methods For Treating Hcv

US Patent:
8466159, Jun 18, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/603022
Inventors:
Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/4965
A61K 31/33
A61K 31/505
A61K 31/47
A61K 31/415
A61K 31/40
US Classification:
51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81
Abstract:
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e. g. , ritonavir), and ribavirin.

Methods For Treating Hcv

US Patent:
8492386, Jul 23, 2013
Filed:
Sep 4, 2012
Appl. No.:
13/603006
Inventors:
Barry M. Bernstein - Mequon WI, US
Rajeev M. Menon - Buffalo Grove IL, US
Amit Khatri - Waukegan IL, US
Sven Mensing - Mannheim, DE
Sandeep Dutta - Gurnee IL, US
Daniel E. Cohen - Wilmette IL, US
Thomas J. Podsadecki - Chicago IL, US
Scott C. Brun - Green Oaks IL, US
Walid M. Awni - Green Oaks IL, US
Emily O. Dumas - Libertyville IL, US
Cheri E. Klein - Northbrook IL, US
Assignee:
AbbVie Inc. - North Chicago IL
International Classification:
A61K 31/4965
A61K 31/33
A61K 31/505
A61K 31/47
A61K 31/415
A61K 31/40
A61K 31/675
US Classification:
51425505, 514183, 514269, 514314, 514397, 514309, 514394, 514422, 514 81
Abstract:
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e. g. , ritonavir).

Controlled Release Formulation Of Divalproex Sodium

US Patent:
2002002, Feb 28, 2002
Filed:
Jun 8, 2001
Appl. No.:
09/877682
Inventors:
Yihong Qiu - Gumee IL, US
J. Bollinger - Libertyville IL, US
Sandeep Dutta - Waukegan IL, US
Howard Cheskin - Glencoe IL, US
Kevin Engh - Kenosha WI, US
Richard Poska - Mundelein IL, US
Kenneth Sommerville - Libertyville IL, US
International Classification:
A61K009/22
US Classification:
424/489000, 424/468000
Abstract:
A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

Possible Relatives

Dipak K Dutta  Abhijit Dutta  Abhik K Dutta  Indira B Dutta  Jennifer Dutta  Jyoti P Dutta  Kamal K Dutta  Sandeep N Nair  Sandeep Singh  Sandeep M Patel 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.